Atieh Okhli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Atieh Okhli has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Anna Ghorbani Doshantapeh
Department of Hematology-Medical Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Khorsid Rigi
Tropical and Communicable Diseases Research Centre, Iranshahr University of Medical Sciences, Iranshahr, Iran
1 shared publication - Kianoush Saberi
Department of Anesthesiology, Medical Faculty, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Niloofar Khosravi
Anesthesiology Department, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publication - Sara Teihou Jorshari
Hematology-Oncology Department, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publication - Seyed Amir Banikarim
Hematology-Oncology Department, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- Open Access
- 22 April 2026
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 11 (2) , e39330
Aspirin limits platelet TXA2-mediated suppression of T-cell immunity to prevent cancer metastasis
Aspirin, a widely used non-steroidal anti-inflammatory drug, has shown promise in cancer prevention and reducing metastatic progression. This medication limits platelet thromboxane A2 (TXA2)-mediated suppression of T-cell immunity, thereby preventing cancer metastasis. Platelets, beyond their role in hemostasis, actively contribute to tumor progression and metastasis by various mechanisms, including shielding circulating tumor cells from immune surveillance and promoting their extravasation. One critical pathway involves platelet-derived TXA2, a potent lipid mediator that can directly suppress anti-tumor T-cell responses. TXA2 promotes immune evasion by inhibiting T-cell activation and proliferation, thus hindering the body’s ability to effectively eliminate cancerous cells. Aspirin’s well-known inhibitory effect on cyclooxygenase-1 (COX-1) is key here, as COX-1 is responsible for TXA2 synthesis in platelets. By irreversibly acetylating COX-1, aspirin effectively reduces TXA2 production. Then, the reduction in platelet TXA2 alleviates its immunosuppressive effects on T-cells, thereby restoring and enhancing anti-tumor immunity. The enhanced T-cell activity can then more effectively target and destroy circulating tumor cells, finally limiting the formation of secondary tumors and preventing metastasis.
- 22 April 2026
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 11 (2) , e39330
Open AccessAspirin limits platelet TXA2-mediated suppression of T-cell immunity to prevent cancer metastasis
Aspirin, a widely used non-steroidal anti-inflammatory drug, has shown promise in cancer prevention and reducing metastatic progression. This medication limits platelet thromboxane A2 (TXA2)-mediated suppression of T-cell immunity, thereby preventing cancer metastasis. Platelets, beyond their role in hemostasis, actively contribute to tumor progression and metastasis by various mechanisms, including shielding circulating tumor cells from immune surveillance and promoting their extravasation. One critical pathway involves platelet-derived TXA2, a potent lipid mediator that can directly suppress anti-tumor T-cell responses. TXA2 promotes immune evasion by inhibiting T-cell activation and proliferation, thus hindering the body’s ability to effectively eliminate cancerous cells. Aspirin’s well-known inhibitory effect on cyclooxygenase-1 (COX-1) is key here, as COX-1 is responsible for TXA2 synthesis in platelets. By irreversibly acetylating COX-1, aspirin effectively reduces TXA2 production. Then, the reduction in platelet TXA2 alleviates its immunosuppressive effects on T-cells, thereby restoring and enhancing anti-tumor immunity. The enhanced T-cell activity can then more effectively target and destroy circulating tumor cells, finally limiting the formation of secondary tumors and preventing metastasis.